Gourt > Health > Pharmacy > Drugs and Medications > E > Emtricitabine
Emtricitabine (FTC), with trade name Emtriva® (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults.
Emtricitabine is also marketed in a fixed-dose combination with tenofovir (Viread®) under the brand name Truvada®. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva®, marketed by Bristol-Myers Squibb) has been approved by the FDA on July 12, 2006 under the brand name Atripla®.
History
Emtricitabine was discovered by Dr. Dennis Liotta, Dr. Raymond Schinazi and Dr. Woo-Baeg Choi of Emory University and licensed to Triangle Pharmaceuticals by Emory in 1996. Triangle Pharmaceuticals was acquired in 2003 by Gilead Sciences, who completed development and now market the product with the brand name Emtriva®. More on [ Emtricitabine ]
frédy (visiteur): Truvada, nouvelle association contre le VIH : Emtricitabine plus ténofovir disoproxil: salut Mat... http://bit.ly/313Czo
vih (L'info des séropos) Mon, 19 Oct 2009 09:46:21 -0000
frédy (visiteur): Truvada, nouvelle association contre le VIH : Emtricitabine plus ténofovir disoproxil: salut Mat... http://bit.ly/313Czo
frédy (visiteur): Truvada, nouvelle association contre le VIH : Emtricitabine plus ténofovir disoproxil: sa.. http://bit.ly/313Czo #vih
survivreausida (survivreausida.net) Mon, 19 Oct 2009 09:44:11 -0000
frédy (visiteur): Truvada, nouvelle association contre le VIH : Emtricitabine plus ténofovir disoproxil: sa.. http://bit.ly/313Czo #vih
Emtriva - Features prescribing information (PDF) and press releases from the manufacturer, Gilead.
Meta Description: [ Emtriva (an antiretroviral agent for the treatment of HIV-1 infection) is a one capsule, once-daily nucleoside reverse transcriptase inhibitor for use in combination with other antiretroviral drugs ]
Emtriva Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.
Meta Description: [ Consumer Information Sheet ]
| FDA Studying Heart Attack Risk with Ziagen, Videx -July 2008 | |
